摘要
目的探讨晚期非小细胞肺癌(NSCLC)患者化疗前后血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和糖类抗原(CA125)的变化。方法选取2013年8月至2015年8月间辽宁省本溪市本钢总医院经病理以及细胞学诊断证实的NSCLC患者42例为研究组,化疗前采用酶联免疫法测定患者血清CEA、CYFRA21-1和CA125表达水平,化疗治疗结束3周后再次测定患者血清中CEA、CYFRA21-1和CA125表达水平变化,并行胸部CT检查,根据结果分为化疗有效者(完全缓解+部分缓解)和无效者(病情稳定+疾病进展)。选取同期来院体检的42例健康者为对照组,均排除肺部疾病,与研究组患者血清中CEA、CYFRA21-1和CA125水平变化进行比较。结果研究组患者化疗前血清CEA、CYFRA21-1和CA125水平分别为(38.78±10.37)ng/ml、(3.51±1.37)ng/ml和(37.22±15.39)U/ml,对照组患者分别为(1.86±0.47)ng/ml、(2.0±0.11)ng/ml和(20.1±15.7)U/ml,两组比较差异有统计学意义(P<0.05)。研究组患者化疗前血清CEA、CYFRA21-1和CA125在化疗有效组和无效组中无显著统计学意义(P<0.05)。化疗后血清CEA、CYFRA21-1和CA125在治疗有效组明显低于化疗前,有显著统计学意义(P<0.05);在无效组化疗后血清CEA、CYFRA21-1和CA125表达水平与化疗前相比差异不大,无统计学意义(P>0.05)。结论对临床NSCLC患者进行血清CEA、CYFRA21-1和CA125检测,可有效评估患者临床疗效及预后,为临床NSCLC化疗疗效提供标准依据。
Objective To investigate the changes of serum CA125,CYFRA21-1 and CEA in patients with advanced non-small cell lung cancer（ NSCLC） before and after chemotherapy. Methods From August 2013 to August 2015,42 patients with a pathological and cytological diagnosis of NSCLC were selected as the observation group at The General Hospital of Benxi Iron and Steel Group. The expression level of serum CEA,CYFRA21-1 and CA125 was measured using enzyme-linked immunosorbent assay before chemotherapy and at 3 weeks after the end of chemotherapy,and chest CT examination was performed then. According to the CT results,patients were divided into chemotherapy effective subgroup（ complete remission and partial remission） and ineffective subgroup（ stable disease and progressive disease）. Forty-two healthy examination clients were selected simultaneously as controls. Changes of serum CEA,CYFRA21-1 and CA125 levels were compared between the two groups with lung diseases excluded. Results Before chemotherapy,the serum levels of CEA,CYFRA21-1 and CA125 were（ 38. 78 ± 10. 37） ng /ml,（ 3. 51 ± 1. 37） ng /ml and（ 37. 22 ± 15. 39） U /ml for the observation group（ 1. 86 ± 0. 47） ng / ml,（ 2. 0 ± 0. 11） ng / ml and（ 20. 1 ± 15. 7） U / ml for the control group respectively（ P 〈 0. 05）. For the the observation group,there was no significant difference in the changes of serum CEA,CYFRA21-1 and CA125 between effective subgroup and ineffective subgroup before chemotherapy（ P 〈 0. 05）. Serum CEA,CYFRA21-1 and CA125 levels were significant lower in the effective subgroup after chemotherapy than before chemotherapy（ P 〈 0. 05）. For the ineffective subgroup,there was no statistical difference in the changes of serum levels of CEA,CYFRA21-1 and CA125 before and after chemotherapy（ P 〉 0. 05）. Conclusion Serum CYFRA21-1,CA125 and CEA can effectively predict the clinical efficacy and prognosis in patients with NSCLC.
出处
《中国肿瘤临床与康复》
2016年第12期1417-1420,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
